<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132954">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02089178</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0937</org_study_id>
    <nct_id>NCT02089178</nct_id>
  </id_info>
  <brief_title>Comparison of the Effect of Total Intravenous Anesthesia and Inhalation Anesthesia on Cancer Cell Cytotoxicity, Micrometastasis and Recurrence of Tumor in Patients Undergoing Breast Tumor Resection</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of total intravenous anesthesia and
      inhalation anesthesia on cancer cell cytotoxicity, micrometastasis and recurrence of tumor
      in patients undergoing breast tumor resection. Using propofol-remifentanil in total
      intravenous anesthesia group and sevoflurane -remifentanil in inhalation anesthesia group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>number of NK cell</measure>
    <time_frame>at 24 hour after surgery.</time_frame>
    <safety_issue>No</safety_issue>
    <description>comparison of the effect of total intravenous anesthesia and inhalation anesthesia on cancer cell cytotoxicity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the total intravenous anesthesia group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inhalation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the inhalation anesthesia group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intravenous anesthesia</intervention_name>
    <description>total intravenous anesthesia group: propofol-remifentanil</description>
    <arm_group_label>intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>inhalation anesthesia</intervention_name>
    <description>inhalation anesthesia group: sevoflurane-remifentanil</description>
    <arm_group_label>inhalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol-remifentanil</intervention_name>
    <arm_group_label>intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane-remifentanil</intervention_name>
    <arm_group_label>inhalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient between 20 and 65 of age with ASA physical status Ⅰ-Ⅲ

          -  breast cancer patients with no sign of local invasion (adjacent organs) and distant
             metastasis revealed by imaging studies

          -  surgery performed by the same surgical team

        Exclusion Criteria:

          -  ASA physical status Ⅳ

          -  hepatic and renal impairment

          -  diabetes or other endocrine disorders

          -  body mass index &gt; 35 kg/m2

          -  immune disorders or immunosuppressive therapy

          -  steroid treatment in the last 6 months

          -  inflammation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bon Nyeo Koo, MD</last_name>
    <phone>82-2-2228-2420</phone>
    <email>koobn@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bon Nyeo Koo, MD</last_name>
      <phone>82-2-2228-2420</phone>
      <email>koobn@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Bon Nyeo Koo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 14, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>total intravenous anesthesia, inhalation anesthesia, cancer cell cytotoxicity, breast tumor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
